Board of Directors

Dr. Caforio, age 57, serves as chairman of Bristol Myers Squibb’s Board of Directors.

Dr. Caforio has been our chief executive officer since May 2015. He was our chief executive officer designate from January to May 2015, our chief operating officer from June 2014 to May 2015, and he served as executive vice president and chief commercial officer from November 2013 to June 2014.

From October 2011 to November 2013, he served as president, U.S. He held the position of senior vice president, Global Commercialization and Immunology from May 2010 to October 2011. Prior to that, he served as senior vice president, Oncology, U.S. and Global Commercialization from March 2009 to May 2010.

From January 2007 to March 2009, he served as senior vice president, U.S. Oncology and from May 2004 to January 2007, he served as senior vice president, European Marketing and Brand Commercialization.

Dr. Caforio is a member of the Board of Directors of Stryker, a member of the CEO Roundtable on Cancer as well as the Pharmaceutical Research and Manufacturers of America (PhRMA). 

Mr. Samuels, age 67, has been the Lead Independent Director of Bristol-Myers Squibb since May 2021 and has served on the Board since February 2017. With more than 35 years in the financial industry, Mr. Samuels brings to the Board extensive business and operational experience, particularly with respect to economics, capital markets and investment decision making. Mr. Samuels was president of Capital Guardian Trust Company from 2010 until 2016 and a global equity portfolio manager at Capital Group, one of the most prominent investment management organizations in the world from 1990 until 2016. While at Capital Group, he served on numerous management and investment committees, with an eye towards long-term shareholder value creation. He also serves as co-chair of Tuft’s President’s Council.

Mr. Samuels currently serves as a director at Perrigo Company, PLC, and Centene Corporation.

Mr. Arduini, age 57, has been president and chief executive officer of GE Healthcare, a global medical technology, pharmaceutical diagnostics, and digital solutions innovator, since January 2022.

He served as president and chief executive officer of Integra LifeSciences Holdings Corporation from January 2012 to December 2021 and was president and chief operating office from November 2010 to January 2012. Before joining Integra, Mr. Arduini was corporate vice president and president of Medication Delivery, Baxter Healthcare, from 2005 to 2010.

Prior to joining Baxter, Mr. Arduini worked for General Electric Healthcare, where he spent 15 years in a variety of management roles for domestic and global businesses, culminating in leading the global functional imaging business.

Mr. Arduini also serves on the Board of Directors of ADVAMED (the Advanced Medical Technology Association) and the Board of Directors of the National Italian American Foundation. Mr. Arduini also serves on the Board of Trustees of Susquehanna University.

Dr. Bhatt, age 54, has served as the executive director of interventional cardiovascular programs at Brigham and Women’s Hospital since 2013. He is also a professor of medicine at Harvard Medical School.

Dr. Bhatt brings to the Board more than 20 years of research experience in acute coronary syndromes, preventive cardiology, and advanced techniques in cardiac, cerebral, and peripheral intervention. He has served as the principal or co-principal investigator for cardiovascular clinical trials focused on interventional cardiology, anti-thrombotic therapy, lipid-lowering therapy, heart failure, obesity, and diabetes, among other areas.

Prior to his current position, Dr. Bhatt served as chief of cardiology at VA Boston Healthcare from 2008-2013. From 2001-2008, Dr. Bhatt held a number of roles of increasing responsibility at the Cleveland Clinic in Cleveland, Ohio. In addition to being an attending physician, he served as an associate director of the Cleveland Clinic Cardiovascular Coordinating Center, director of the interventional cardiology fellowship, as well as the associate director of the cardiovascular medicine fellowship.

Dr. Haller, age 67, has served since 2007 as ophthalmologist-in-chief of Wills Eye Hospital in Philadelphia, PA, where she holds the William Tasman, MD endowed chair. She is professor and chair of the department of ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University and Thomas Jefferson University Hospitals.

A magna cum laude graduate of Princeton, Dr. Haller received her MD degree from Harvard Medical School. She trained at the Wilmer Eye Institute at Johns Hopkins where she served as the first female chief resident. She then joined the Johns Hopkins faculty, where she held the Katharine Graham Chair in Ophthalmology before her move to lead Wills.

One of the world's most renowned retina surgeons, Dr. Haller has innovated translational advances against blindness on many fronts, including sustained drug delivery devices, ocular pharmacotherapy, retinal "chip" implants, gene therapy, telemedicine and combating health care disparities. Elected to the National Academy of Medicine, she has held many leadership roles in medicine, is a past member of the Board of Trustees of Princeton University, and a consultant at Children’s Hospital of Philadelphia. She previously served on the Celgene Board of Directors, where she was a member of the Audit Committee.

Dr. Haller currently serves as a director at Ophtea Limited, Eyenovia, Inc., and Outlook Therapeutics, Inc.

Dr. Hidalgo, age 54, has served as chief of the division of hematology and medical oncology at Weill Cornell Medicine/New York-Presbyterian Hospital since 2019 and is responsible for leading clinical and translational research in hematology, vascular biology and oncology. He is also the E. Hugh Luckey distinguished professor of medicine and associate director for clinical services at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine.

Dr. Hidalgo brings to the Board more than 20 years of experience in translational and clinical research in anticancer drug development, with an emphasis in gastrointestinal cancers. He has also led the early clinical development of new anticancer agents for pancreatic cancer among other solid tumor cancers.

Prior to his current position, Dr. Hidalgo served as chief of the division of hematology at Beth Israel Deaconess Medical Center in Boston and clinical director of the Rosenberg Clinical Cancer Center from 2015 to 2019. During this time, he was the Theodore W. and Evelyn G. Berenson professor of medicine at Harvard Medical School. Dr. Hidalgo also held leadership positions at the Spanish National Cancer Research Centre (CNIO) in Madrid and at the Kimmel Comprehensive Cancer Center, where he was director of gastrointestinal oncology program.

Ms. Price, age 60, has more than 30 years of financial and operational experience. Most recently, she served as executive vice president (EVP) and chief financial officer (CFO) of Macy’s, Inc. until May 2020.

Prior to that, she was a full-time senior lecturer for Harvard Business School in the accounting and management unit from 2014 to 2018. Before that, Ms. Price also served as EVP and CFO for Ahold USA, controller and chief accounting officer (CAO) of CVS Caremark Corporation, and in senior leadership positions at JPMorgan Chase, Prudential Financial, Diageo and Kraft Foods. A certified public accountant (CPA), she began her career at Arthur Andersen & Co.

Ms. Price currently serves on the Boards of Directors of Accenture plc and Warner Bros. Discovery. She previously served on the Board of Directors of Dollar General Corporation and DaVita, Inc. Ms. Price earned her MBA degree from the University of Chicago and her BS degree in accountancy from DePaul University.

Mr. Rice, age 57, served as executive vice president (EVP) of CVS Health and president of its pharmacy benefits management (PBM) business, CVS Caremark, where he led the PBM business from March 2018 to February 2020.

Prior to that, he served as the EVP of global services and CFO for Eli Lilly and Company from 2006 to 2017. During his 27-year tenure at Eli Lilly, Mr. Rice was instrumental in helping to drive the company’s innovation strategy and held numerous roles in finance and operations.

He is currently a member of The Walt Disney Company’s Board of Directors and previously served on the Board of Directors of Target Corporation. Mr. Rice holds an MBA degree from Indiana University and a BS degree in electrical engineering from Kettering University.

Mr. Storch, age 65, has served as chief executive officer of Storch Advisors, a global business and advisory firm, since November 2017. From November 2013 to January 2015, he served as chairman and chief executive officer.

He served as chief executive officer of Hudson’s Bay Company from January 2015 to November 2017. He also served as chairman of Toys“R”Us, Inc. from February 2006 to November 2013 and chief executive officer of Toys“R”Us from February 2006 to May 2013.

Prior to joining Toys“R”Us, Mr. Storch served as vice chairman of Target Corporation. He joined Target in 1993 as senior vice president of strategy and served in roles of increasing seniority over the next 12 years. Prior to joining Target, Mr. Storch was a partner at McKinsey & Company.

He is a director of Fanatics, Inc.

Dr. Vousden, age 64, has been a senior group leader at The Francis Crick Institute in London since February 2017 and chief scientist of Cancer Research UK (CRUK) since July 2016. From 2002 to 2016, she served as the director of the CRUK Beatson Institute in Glasgow, prior to which she held leadership roles at the National Cancer Institute in Maryland from 1995 to 2002.

Dr. Vousden brings to the Board more than 30 years of experience leading groundbreaking cancer research. She is a fellow of the Royal Society and a foreign associate of the National Academy of Sciences. She serves as a member of the Science Advisory Boards of Kovina Therapeutics, the University Cancer Center Frankfurt, Ludwig Institute for Cancer Research, PMV Pharma, Raze Therapeutics, Swiss Institute for Experimental Cancer Research, and Volastra Therapeutics. Dr. Vousden serves as president of the British Association of Cancer Research.

Ms. Yale, age 64, serves as an advisory partner with Bain & Company where she has worked since 1982. Ms. Yale has served in a number of leadership roles at Bain and has been a leader in building Bain's healthcare practice over the last 35 years. She has spent her career advising healthcare providers across the full continuum of care, health insurers, and the private equity investors who invest in healthcare services. She brings to the Board a deep knowledge of the U.S. healthcare system.

She is currently chair of the Board of Blue Cross Blue Shield of Massachusetts and serves on the Board of DaVita, Inc. Previously, Ms. Yale has served on the boards of various healthcare providers and payers: Kindred Healthcare, Inc. (post-acute care), National Surgical Hospitals, Inc. (specialty hospitals), Value Options (managed behavioral healthcare), Pediatric Services of America (home care) and NeighborCare, Inc (institutional pharmacy). She also serves on a number of advisory boards, including for the Harvard Business School Healthcare Initiative and the Health Policy and Management Department at the Harvard Chan School of Public Health.

She also serves on the non-profit board of The Trustees of Reservations, a conservation and preservation organization.